Sargent Bickham Lagudis’s Ionis Pharmaceuticals IONS Stock Holding History

Sargent Bickham Lagudis’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-43	Closed	-$2K	–	1056
2022 Q2	$2K	Hold	43	–	–	﹤0.01%	926
2022 Q1	$2K	Hold	43	–	–	﹤0.01%	888
2021 Q4	$1K	Hold	43	–	–	﹤0.01%	915
2021 Q3	$1K	Hold	43	–	–	﹤0.01%	907
2021 Q2	$2K	Hold	43	–	–	﹤0.01%	864
2021 Q1	$2K	Hold	43	–	–	﹤0.01%	859
2020 Q4	$2K	Hold	43	–	–	﹤0.01%	809
2020 Q3	$2K	Hold	43	–	–	﹤0.01%	730
2020 Q2	$3K	Hold	43	–	–	﹤0.01%	685
2020 Q1	$2K	Hold	43	–	–	﹤0.01%	705
2019 Q4	$3K	Hold	43	–	–	﹤0.01%	740
2019 Q3	$3K	Hold	43	–	–	﹤0.01%	659
2019 Q2	$3K	Hold	43	–	–	﹤0.01%	695
2019 Q1	$3K	Buy	+43	New	+$2.77K	﹤0.01%	731
2017 Q4	–	Sell	-112	Closed	-$6K	–	810
2017 Q3	$6K	Hold	112	–	–	﹤0.01%	678
2017 Q2	$6K	Hold	112	–	–	﹤0.01%	638
2017 Q1	$5K	Hold	112	–	–	﹤0.01%	661
2016 Q4	$5K	Hold	112	–	–	﹤0.01%	626
2016 Q3	$4	Hold	112	–	–	﹤0.01%	659
2016 Q2	$3K	Hold	112	–	–	﹤0.01%	648
2016 Q1	$5K	Buy	+112	New	+$4.55K	﹤0.01%	626

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Sargent Bickham Lagudis's IONS Position: Q3 2022 in Review

Sargent Bickham Lagudis sold out of Ionis Pharmaceuticals (IONS) in Q3 2022, closing a stake of 43 shares — an estimated $2K sold.

Sargent Bickham Lagudis first reported a position in IONS in Q1 2016 and held it in 21 quarters. The position peaked at $6K in Q3 2017. 349 funds tracked by Wall St. Rank hold IONS as of Q3 2022.

Sargent Bickham Lagudis reported no remaining Ionis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Sargent Bickham Lagudis sold 43 Ionis Pharmaceuticals shares in Q3 2022, an estimated $2K.
Sargent Bickham Lagudis first reported a position in Ionis Pharmaceuticals in Q1 2016 and held it in 21 quarters.
Sargent Bickham Lagudis's Ionis Pharmaceuticals position peaked at $6K in Q3 2017.
349 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q3 2022, filed 27 Oct 2022.